GenSight Biologics will present 4 posters related to both clinical-stage product candidates at ARVO Annual Meeting in Honolulu, Hawaï.

=> GS010 – Leber’s Hereditary Optic Neuropathy (LHON) 

Abstract/Presentation Title: Visual Acuity and Safety Outcomes 2.5 Years Post-Treatment with rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON: Results of a Phase I/II Trial

  • Presentation Number – Posterboard Number: 4530 – A0045
  • Session Number: 442
  • Session Title: Ocular gene therapies and chemical therapeutics
  • Session Date/Times: May 2, 2018 from 11:15 AM to 1:00 PM

Abstract/Presentation Title: Impact of sequential bilateral intravitreal injection of rAAV2/2-ND4 on ocular and systemic humoral immune status in non-human primates

  • Presentation Number – Posterboard Number: 4537 – A0052
  • Session Number: 442
  • Session Title: Ocular gene therapies and chemical therapeutics
  • Session Date/Times: May 2, 2018 from 11:15 AM to 1:00 PM

Abstract/Presentation Title: Intravitreal injection of rAAV2/2-ND4 in LHON: absence of correlation between ocular inflammation and humoral or cellular immune responses to AAV2

  • Presentation Number – Posterboard Number: 4531 – A0046
  • Session Number: 442
  • Session Title: Ocular gene therapies and chemical therapeutics
  • Session Date/Times: May 2, 2018 from 11:15 AM to 1:00 PM

=> GS030 – Optogenetics in Retinitis Pigmentosa (RP) 

Abstract/Presentation Title: Ocular Safety of AAV2.7m8-ChrimsonR-tdTomato (GS030-DP) following intravitreous injection and exposure to 595 nm LED light in blind rd1 mice

  • Presentation Number – Posterboard Number: 5658 – A0377
  • Session Number: 515
  • Session Title: Gene therapy, implants
  • Session Date/Times: May 3, 2018 from 8:15 AM to 10:00 AM